Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.92 (1y: -19%)
Market Cap 21.09 M P/E(ttm)
Enterprise Value 16.05 M P/B
OCLS- NAS (USA)
Oculus Innovative Sciences, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.92
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry		 vs
history
Cash to Debt 1.035
OCLS's Cash to Debt is ranked lower than
53% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.43 vs. OCLS: 1.035 )
OCLS' s 10-Year Cash to Debt Range
Min: 1.04   Max: No Debt
Current: 1.04
Equity to Asset -0.111
OCLS's Equity to Asset is ranked lower than
87% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.47 vs. OCLS: -0.111 )
OCLS' s 10-Year Equity to Asset Range
Min: -0.11   Max: 0.69
Current: -0.11
-0.11
0.69
F-Score: 5
Z-Score: -13.55
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) -50.70
OCLS's Operating margin (%) is ranked lower than
81% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. OCLS: -50.70 )
OCLS' s 10-Year Operating margin (%) Range
Min: -1202.9   Max: -7.4
Current: -50.7
-1202.9
-7.4
Net-margin (%) -57.5
OCLS's Net-margin (%) is ranked lower than
84% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.30 vs. OCLS: -57.5 )
OCLS' s 10-Year Net-margin (%) Range
Min: -1219   Max: -8.4
Current: -57.5
-1219
-8.4
ROA (%) -93.5
OCLS's ROA (%) is ranked lower than
89% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. OCLS: -93.5 )
OCLS' s 10-Year ROA (%) Range
Min: -324.1   Max: -9.9
Current: -93.5
-324.1
-9.9
ROC (Joel Greenblatt) (%) -598.20
OCLS's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.00 vs. OCLS: -598.20 )
OCLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15109.4   Max: -585.5
Current: -598.2
-15109.4
-585.5
Revenue Growth (%) 8.8
OCLS's Revenue Growth (%) is ranked higher than
83% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. OCLS: 8.8 )
OCLS' s 10-Year Revenue Growth (%) Range
Min: -21.3   Max: 38
Current: 8.8
-21.3
38
EBITDA Growth (%) -31.5
OCLS's EBITDA Growth (%) is ranked lower than
57% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.50 vs. OCLS: -31.5 )
OCLS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 220.2
Current: -31.5
0
220.2
EPS Growth (%) -29.5
OCLS's EPS Growth (%) is ranked lower than
53% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.15 vs. OCLS: -29.5 )
OCLS' s 10-Year EPS Growth (%) Range
Min: -44.2   Max: 220.5
Current: -29.5
-44.2
220.5
ยป OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q1 2012

OCLS Guru Trades in Q1 2012

Jim Simons 10,300 sh (New)
Chuck Royce Sold Out
» More
Q2 2012

OCLS Guru Trades in Q2 2012

Jim Simons 12,500 sh (+21.36%)
» More
Q3 2012

OCLS Guru Trades in Q3 2012

Jim Simons 10,200 sh (-18.4%)
» More
Q4 2012

OCLS Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OCLS



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/S 1.17
OCLS's P/S is ranked higher than
66% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. OCLS: 1.17 )
OCLS' s 10-Year P/S Range
Min: 0.84   Max: 18.2
Current: 1.17
0.84
18.2
PFCF 55.90
OCLS's PFCF is ranked lower than
96% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.35 vs. OCLS: 55.90 )
OCLS' s 10-Year PFCF Range
Min: 40.5   Max: 85.29
Current: 55.9
40.5
85.29
EV-to-EBIT 62.5
OCLS's EV-to-EBIT is ranked lower than
63% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.12 vs. OCLS: 62.5 )
OCLS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 62.5

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 28
OCLS's Price/Net Current Asset Value is ranked higher than
68% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. OCLS: 28 )
OCLS' s 10-Year Price/Net Current Asset Value Range
Min: 3.2   Max: 63
Current: 28
3.2
63
Price/Median PS Value 0.2
OCLS's Price/Median PS Value is ranked lower than
64% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.90 vs. OCLS: 0.2 )
OCLS' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 3.2
Current: 0.2
0.5
3.2
Forward Rate of Return (Yacktman) -129.33
OCLS's Forward Rate of Return (Yacktman) is ranked lower than
59% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.11 vs. OCLS: -129.33 )
OCLS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.1   Max: 75.4
Current: -129.33
-3.1
75.4

Business Description

Oculus Innovative Sciences, Inc. was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.
Company Website
SEC Reports
Industry: Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO
Traded in other countries:O8Z1.Germany
ยป More Articles for OCLS

Headlines

Articles On GuruFocus.com
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 09 2009 
Weekly CFO Buys Highlight: Information Services Group Inc., BioFuel Energy Corp., Oculus Innovative Nov 22 2009 
Weekly CFO Buys Highlight: Information Services Group, Magnum Hunter Resources, Columbia Laboratorie Nov 15 2009 
Oculus Innovative Sciences Inc. (OCLS) CFO Robert E Miller buys 13,000 Shares Nov 12 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial